Medtronic Stock Is Still A Great “Buy”

Summary:

• Medtronic remains a “Buy” due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months.
• The company posted solid Q2 results with revenue up 5.25% YoY and expects organic revenue growth of 4.75%-5% for fiscal 2025.
• Medtronic’s strategic acquisitions and focus on innovation and efficiency are expected to drive sustainable growth and improve margins over the next 1-3 years.
• As the newly launched products and less supply pressures give a great chance for better margins in the next few years, I believe that MDT should eventually reprice higher.
• I remain bullish on this stock and reiterate my “Buy” rating, hoping for a better 2025.

Intro & Thesis

One of the largest medical technology and solution providers in the world – Medtronic plc (NYSE:MDT) – offers several hundred innovative solutions as its products are targeted at cardiac rhythm management, spinal and surgical

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MDT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Hold On! Can’t find the equity research you’ve been looking for?

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing! There is a free trial and a special discount of 10% for you. Join us today!